Updated Berenberg outlook for UPM‑Kymmene: lower sales, earnings, but a €23.50 target. Learn how price pressures, a forest‑products spin‑off and bio‑fuel focus shape investor sentiment.
UPM‑Kymmene and Andritz team up to fast‑track high‑value tissue innovation, cutting costs, shortening time‑to‑market, and boosting sustainability for SMEs.
UPM‑Kymmene pauses two pulp mills to cut costs, protect margins and focus on high‑margin products amid rising energy, carbon and supply‑chain pressures.
UPM‑Kymmene launches UPM PharmaSure, Vetro, and Endurance, high‑performance adhesives that keep labels bonded through sterilisation, cold‑chain, humidity, and chemical stress—boosting compliance, durability, and sustainability in pharma, spirits, an…
UPM‑Kymmene’s Q1 2026 earnings call highlights record renewable‑energy earnings and a strategic push into renewable fibre, advanced materials, and decarbonisation, underscoring governance excellence and growth amid market volatility.
UPM‑Kymmene’s steady cash flow, high dividend yield, and fast‑growing biochemicals arm it against paper‑cycle volatility, yet commodity‑driven valuation still limits upside.
UPM‑Kymmene’s €0.75 dividend triggered futures price tweaks, yet shares fell only 3 % amid a rally in European basic‑resources stocks—highlighting how corporate actions and macro drivers shape forest‑material market dynamics.